BlossomHill Therapeutics received FDA Fast Track designation for BH-30643, a macrocyclic OMNI-EGFR inhibitor targeting EGFR C797S-positive NSCLC after third-generation TKI therapy. The drug is being evaluated in the SOLARA Phase 1/2 trial across more than 40 sites in 10 countries, addressing a population with no approved oral targeted therapies.
BlossomHill Therapeutics won FDA Fast Track designation for BH-30643, its macrocyclic OMNI-EGFR inhibitor targeting EGFR C797S-positive non-small cell lung cancer after third-generation TKI therapy.
"Fast Track designation is an important regulatory milestone and reflects FDA's recognition, based on its review of our preliminary data, of the potential for BH-30643 to address a significant unmet medical need in this molecularly defined population, for which no oral targeted therapies are approved," Geoff Oxnard, M.D., Chief Medical Officer at BlossomHill Therapeutics, said.
BH-30643 is being evaluated in SOLARA, a global Phase 1/2 first-in-human trial enrolling patients at more than 40 sites in 10 countries. The trial includes dose expansion cohorts in both TKI-pretreated and TKI-naïve settings, including a C797S resistance cohort. In preclinical studies, the compound demonstrated potent inhibitory activity across diverse EGFR mutation categories — classical activating mutations, on-target resistance mutations such as C797S with or without T790M, atypical mutations and exon 20 insertions — while maintaining marked selectivity over wild-type EGFR.
Fast Track designation enables more frequent FDA interactions, rolling review of a New Drug Application, and potential eligibility for Accelerated Approval and Priority Review if criteria are met. The designation applies to a patient population for which no oral targeted therapies are currently approved, according to the company.
BlossomHill went public on Aug. 6 with an upsized $150 million initial public offering, and shares traded at $16.85 pre-market, up 2.87 percent, following the announcement. The company is led by J. Jean Cui, Ph.D., who previously developed three FDA-approved oncology drugs.
The company's pipeline also includes BH-30236, a macrocyclic CLK inhibitor in development for relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndrome, and BH-501284, a preclinical pan-KRAS Switch II inhibitor. BlossomHill is headquartered in San Diego, California.
The C797S mutation is a known on-target resistance mechanism that emerges after treatment with third-generation EGFR TKIs such as osimertinib, leaving patients with limited therapeutic options. BH-30643 was designed using modern understanding of mutant EGFR structure and protein dynamics, addressing a gap left by inhibitors discovered more than a decade ago.
The Fast Track designation opens a faster regulatory pathway for a population with no approved oral targeted therapy, potentially accelerating BH-30643's path to market. Investors will watch for interim data from the SOLARA trial, registered as NCT06706076 on clinicaltrials.gov, as the next key event for the stock.
This article is for informational purposes only and does not constitute investment advice.
